


CORRECTION

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico

Ana Patricia Ortiz, Karen J. Ortiz-Ortiz, Moraima Ríos, José Laborde, Amit Kulkarni, Matthew Pillsbury, Andreas Lauschke, Homero A. Monsanto, Cecile Marques-Goyco

There is an error in the third sentence of the second paragraph of the Introduction. The correct sentence is: “In Puerto Rico, cancer was the second leading cause of death by 2010 [8], and cervical cancer accounts for 3.9% of all cancer cases [9].”

There are errors in [Table 1](#). The numbers from the 34%/13% scenario are repeated for the 50%/40% and 80%/64% scenarios. In addition, in the 80%/64% scenario, the years have an inverted order. Please see the corrected [Table 1](#) here.



 OPEN ACCESS

Citation: Ortiz AP, Ortiz-Ortiz KJ, Ríos M, Laborde J, Kulkarni A, Pillsbury M, et al. (2018) Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico. PLoS ONE 13(9): e0204759. <https://doi.org/10.1371/journal.pone.0204759>

Published: September 21, 2018

Copyright: © 2018 Ortiz et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 1. Estimated cumulative incidence costs avoided since HPV4 vaccination program started, by vaccination scenario.

HPV Disease	Vaccination Scenario (34% Female/13% Male)			Vaccination Scenario (50% Female/40% Male)			Vaccination Scenario (80% Female/64% Male)		
	25 years	50 years	100 years	25 years	50 years	100 years	25 years	50 years	100 years
Genital warts-female	\$8,671,954	\$14,257,263	\$18,123,487	\$12,814,209	\$20,640,587	\$26,038,578	\$31,678,147	\$51,246,695	\$64,843,815
Genital warts-male	\$8,108,461	\$13,440,910	\$17,091,889	\$16,223,314	\$26,604,903	\$33,770,465	\$37,975,475	\$62,669,838	\$79,764,797
CIN1	\$841,749	\$1,975,720	\$2,863,853	\$1,151,140	\$2,573,883	\$3,687,742	\$2,771,264	\$5,765,318	\$8,071,479
CIN2/3	\$4,830,393	\$13,375,935	\$20,551,689	\$6,053,998	\$16,289,155	\$24,930,480	\$13,071,331	\$32,275,160	\$48,333,370
Cervical cancer	\$1,215,209	\$4,347,953	\$7,539,668	\$1,522,658	\$5,267,437	\$9,079,015	\$3,365,007	\$10,455,572	\$17,408,785
Total Direct Costs	\$23,667,766	\$47,397,781	\$66,170,586	\$37,765,319	\$71,375,965	\$97,506,280	\$88,861,224	\$162,412,583	\$218,422,246

<https://doi.org/10.1371/journal.pone.0204759.t001>

Reference

1. Ortiz AP, Ortiz-Ortiz KJ, Ríos M, Laborde J, Kulkarni A, Pillsbury M, et al. (2017) Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico. PLoS ONE 12(11): e0184540. <https://doi.org/10.1371/journal.pone.0184540> PMID: 29190725